Chiome Bioscience, Inc. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

147.16

223.47

118.02

113.10

138.70

358.18

158.90

Other Operating Income

0.00

Total Operating income

147.16

223.47

118.02

113.10

138.70

358.18

158.90

Raw Material Cost

66.64

72.06

52.72

54.87

58.06

144.98

74.01

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

0.29

0.26

0.96

1.03

0.91

0.83

0.75

Selling and Distribution Expenses

138.40

135.51

143.50

138.41

141.41

130.09

127.82

Other Expenses

17.42

19.01

18.94

19.10

20.29

19.22

29.61

Total Expenditure (Excl Depreciation)

379.51

397.90

386.54

385.36

403.26

468.09

498.73

Operating Profit (PBDIT) excl Other Income

-232.3

-174.4

-268.5

-272.3

-264.6

-109.9

-339.79999999999995

Other Income

0.30

-7.03

1.09

-0.12

-0.14

5.94

-10.49

Operating Profit (PBDIT)

-229.72

-178.96

-266.19

-272.38

-264.70

-103.68

-350.02

Interest

0.29

0.26

0.96

1.03

0.91

0.83

0.75

Exceptional Items

0.00

9.24

0.00

0.35

0.19

Gross Profit (PBDT)

80.52

151.42

65.30

58.22

80.64

213.20

84.89

Depreciation

2.33

2.50

1.24

0.00

0.29

Profit Before Tax

-232.34

-181.72

-259.15

-273.41

-265.26

-104.61

-350.88

Tax

0.81

0.66

Provisions and contingencies

0.00

Profit After Tax

-233.15

-182.53

-259.96

-274.22

-266.07

-105.28

-351.54

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-233.15

-182.53

-259.96

-274.22

-266.07

-105.28

-351.54

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

-233.15

-182.53

-259.96

-274.22

-266.07

-105.28

-351.54

Equity Capital

0.00

Face Value

0.0

Reserves

1,311.98

1,122.06

1,250.13

1,519.33

1,761.09

1,920.30

1,215.70

Earnings per share (EPS)

-3.31

-2.68

-3.82

-4.04

-3.94

-1.65

-6.06

Diluted Earnings per share

-3.31

-2.68

-3.82

-4.04

-3.94

-1.65

-6.06

Operating Profit Margin (Excl OI)

-157.88%

-78.05%

-227.53%

-240.73%

-190.74%

-30.69%

-213.86%

Gross Profit Margin

-156.3%

-80.19%

-218.54%

-241.75%

-191.25%

-29.13%

-220.63%

PAT Margin

-158.43%

-81.68%

-220.27%

-242.47%

-191.83%

-29.39%

-221.23%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is -34.14% vs 89.41% in Dec 2025

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is -27.78% vs 29.81% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is -33.80% vs 35.69% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is 0.00% vs -70.00% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

Compare Quarterly Results Of Chiome Bioscience, Inc. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(JPY)

Change(%)

Net Sales

147.16

61.60

85.56

138.90%

Other Operating Income

0.00

Total Operating income

147.16

61.60

85.56

138.90%

Raw Material Cost

66.64

8.65

57.99

670.40%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

0.29

1.47

-1.18

-80.27%

Selling and Distribution Expenses

138.40

266.62

-128.22

-48.09%

Other Expenses

17.42

-0.15

17.57

11,713.33%

Total Expenditure (Excl Depreciation)

379.51

275.27

104.24

37.87%

Operating Profit (PBDIT) excl Other Income

-232.35

-213.68

-18.67

-8.74%

Other Income

0.30

11.63

-11.33

-97.42%

Operating Profit (PBDIT)

-229.72

-194.92

-34.80

-17.85%

Interest

0.29

1.47

-1.18

-80.27%

Exceptional Items

0.00

Gross Profit (PBDT)

80.52

52.95

27.57

52.07%

Depreciation

2.33

7.13

-4.80

-67.32%

Profit Before Tax

-232.34

-203.52

-28.82

-14.16%

Tax

0.81

0.71

0.10

14.08%

Provisions and contingencies

0.00

Profit After Tax

-233.15

-204.23

-28.92

-14.16%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-233.15

-204.23

-28.92

-14.16%

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

-233.15

-204.23

-28.92

-14.16%

Equity Capital

0.00

Face Value

0.00

Reserves

1,311.98

2,695.34

-1,383.36

-51.32%

Earnings per share (EPS)

-3.31

-6.00

2.69

44.83%

Diluted Earnings per share

-3.31

-6.00

2.69

44.83%

Operating Profit Margin (Excl OI)

-157.88%

-346.89%

0.00

189.01%

Gross Profit Margin

-156.30%

-318.83%

0.00

162.53%

PAT Margin

-158.43%

-331.55%

0.00

173.12%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 14.72 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -34.14% vs 89.41% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 6.13% vs 7.02% in Mar 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit -23.32 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -27.78% vs 29.81% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 12.36% vs 12.47% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) -23.00 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -33.80% vs 35.69% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 13.08% vs 17.80% in Mar 2025

Quarterly - Interest

Interest 0.03 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 0.00% vs -70.00% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -66.67% vs 50.00% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) -157.88%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025